Tranquil or asleep: Not tranquil or asleep · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes tranquillisation or asleep Not tranquil or asleep compared with OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE (very low certainty).
1 finding from 1 review
Repeated need for rapid tranquillisation ‐ more than 1 injection · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes repeated need for rapid tranquillisation ‐ more that 1 injection compared with OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE (very low certainty).
1 finding from 1 review
Specific behaviour ‐ threat or injury to self or others ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global outcome ‐ not any improvement · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes global outcome ‐ not any improvement compared with OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE (very low certainty).
1 finding from 1 review
Adverse effects ‐ cardiovascular ‐ hypotension · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: specific ‐ cardiovascular ‐ hypotension compared with OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE (very low certainty).
1 finding from 1 review
Adverse effects: specific ‐ seizure · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: specific ‐ central nervous system ‐ seizures compared with OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE (very low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found